Retrospective analysis explores impact of RAAS inhibitors on kidney outcomes in hospitalized AKI patients, suggesting careful evaluation.
Background Although not recommended for potential risk of worsening kidney dysfunction, continuation of renin-angiotensin aldosterone system inhibitor (RAASi) during an episode of acute kidney injury (AKI) is not rare in clinical practice, and the risk-benefit ratio for RAASi therapy should always be carefully evaluated. Limited data exists regarding the reasons for RAASi continuation during the acute course of AKI and its impact on kidney and overall outcomes.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: